Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).-Reference-Cited by-同舟云学术

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

Published:2014-05-20 Issue:15_suppl Volume:32 Page:506-506
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Carey Lisa A.¹,Barry William Thomas²,Pitcher Brandy³,Hoadley Katherine A.⁴,Cheang Maggie Chon U.¹,Anders Carey K.⁵,Henry N. Lynn⁶,Tolaney Sara M.⁷,Dang Chau T.⁸,Krop Ian E.⁷,Harris Lyndsay⁹,Berry Donald A.¹⁰,Perou Charles M.¹¹,Winer Eric P.⁷,Hudis Clifford A.⁸,

Affiliation:

1. The University of North Carolina at Chapel Hill, Chapel Hill, NC

2. Alliance Statistical Center, Dana-Farber Cancer Institute, Boston, MA

3. Alliance Statistical Center, Duke University Medical Center, Durham, NC

4. University of North Carolina, Chapel Hill, NC

5. UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

6. University of Michigan Medical Center, Ann Arbor, MI

7. Dana-Farber Cancer Institute, Boston, MA

8. Memorial Sloan Kettering Cancer Center, New York, NY

9. Case Western/Seidman Cancer Center, Cleveland, OH

10. Alliance Statistics and Data Center, University of Texas MD Anderson Cancer Center, Houston, TX

11. Department of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, NC